Opinion|Videos|August 23, 2024

Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC

Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.

Episodes in this series

When treating with androgen receptor-targeted therapies, what are some of the considerations to make towards the sequencing of these agents and weighing their benefits in first line versus second line?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more